Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for prevention of cognitive impairment during ECT
ACTRN12614000619640Phase 2Recruiting
- Sponsor
- Mohammad Abbasinazari
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in electroconvulsive therapy-associated cognitive impairment (ECT-ICI) comparing Memantine with Placebo (2 arms). Primary endpoints: Modified Mental Status Examination score after ECT and Modified Mental Status Examination score before ECT. Started Feb 2014; status: recruiting.
02
Drugs
memantine
03
Conditions
electroconvulsive therapy-associated cognitive impairment (ECT-ICI)
Beyond the preview
Go deeper on ACTRN12614000619640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000619640.